Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201354 | 0.89 | TGFBR1 (0.46) | TGFBR1MAPK14THRBALDH1A1POLB | |
| SCHEMBL27648484 | 0.87 | TGFBR1 (0.52) | TGFBR1MAPK14CCR1CCR8METAP2 | |
| SCHEMBL5491962 | 0.86 | TGFBR1 (0.56) | TGFBR1MAPK14THRBHPGDCCR1 | |
| SCHEMBL12645997 | 0.84 | TGFBR1 (0.61) | TGFBR1MAPK14THRBCCR1CCR8 | |
| SCHEMBL5492614 | 0.80 | TGFBR1 (0.58) | TGFBR1MAPK14THRBCCR1CCR8 | |
| SCHEMBL28758711 | 0.79 | TGFBR1 (0.45) | TGFBR1MAPK14CCR1CCR8METAP2 | |
| SCHEMBL5200287 | 0.78 | MEN1 (0.40) | TGFBR1ALDH1A1POLBMAPTHPGD | |
| SCHEMBL5138951 | 0.78 | TGFBR1 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL27648474 | 0.77 | METAP2 (0.39) | TGFBR1MAPK14THRBCCR1CCR8 | |
| SCHEMBL5198226 | 0.77 | TGFBR1 (0.46) | TGFBR1MAPK14THRBCCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| US-7276525-B2 | Osteogenesis-promotion enhancer and method of screening the same | NIPPON SHINYAKU CO. LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20060183778-A1 | Osteogenesis-promotion enhancer and method of screening the same | JAPANESE FOUNDATION OF CANCER RESEARCH (JP) | 2006-08-17 | — | — | US | disclosed |
| EP-1632249-A1 | OSTEOGENESIS-PROMOTION ENHANCER AND METHOD OF SCREENING THE SAME | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.